Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 39Neoplasms 37Depression 29Prostatic Neoplasms 23Fatigue 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 13Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Pain 11Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 11Lymphoma, Large-Cell, Immunoblastic 10Leukemia, Myeloid, Acute 10Colorectal Neoplasms 10Leukemia, Myeloid, Chronic-Phase 9Hodgkin Disease 9Blast Crisis 9Vomiting 8Nausea 8Lymphoma 8Leukemia, Myeloid, Accelerated Phase 8Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7

Interventions

pembrolizumab 7Radiotherapy 3Proton Therapy 3Interleukin-2 3Cyclophosphamide 3spartalizumab 2fludarabine 2Rosuvastatin Calcium 2Paclitaxel 2Ipilimumab 2Immune Checkpoint Inhibitors 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2toripalimab 1tislelizumab 1sotorasib 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1niraparib 1neotil 1necitumumab 1mirdametinib 1leronlimab 1lenvatinib 1atezolizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumor, Adult × Therapeutics × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡